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Recently, a family of growth factors has been described that activates erbB-2 
receptors. These factors, known as the neu differentiation factors (NDF) or hereg- 
ulins (HRG), induce tyrosine phosphorylation of erbB-2 receptors as a result of 
their direct interaction with either erbB-3 or erbB-4 receptors. Although it is  
known that expression of erbB-2 receptors has relevance in human breast cancer 
progression, how erbB-2, -3 and -4 receptors regulate mammary epithelial cell 
proliferation i s  not known. Therefore, experiments were carried out to study the 
mitogenic activity of NDF/HRG on the human mammary epithelial cell line MCF- 
1 OA which can be cultured continuously under serum-free conditions. MCF-1 OA 
cells, like primary cultures of normal human mammary epithelial cells, express an 
absolute requirement for exogenous epidermal growth factor (EGF) and insulin- 
like growth factor I (IGF-I) for growth. The results of these experiments indicate 
that NDF/HRG can induce tyrosine phosphorylation of pl85erbB-2 in MCF-1OA 
cells and i s  mitogenic for these cells. This is  consistent with the coexpression of 
erbB-2 and erbB-3 mRNA that we have observed in MCF-1 OA cells. In addition, 
we found that NDF/HRG can substitute for either EGF or IGF-I to stimulate prolif- 
eration of these cells. The ability to substitute for both EGF and IGF-I i s  a unique 
property of NDF/HRG and is not shared by other members of the EGF or IGF 
family of growth factors, nor by other factors that we have studied. A striking 
isoform specificity was also observed which indicated that the p-isoforms of 
NDF/HRG were greater than ten times more mitogenic than the a-isoforms. We 
also examined the mitogenic activity of NDF/HRG on MCF-1OA cells that overex- 
press the erbB-2 receptor as a result of infection with a retroviral vector containing 
the human c-erbB-2 gene (MCF-1 OAerbB-2 cells). These studies indicated that 
MCF-1 OAerbB-2 cells have increased sensitivity to the mitogenic effects of NDF/ 
HRG and that these cells are responsive to the a-isoforms of NDF/HRG at physio- 
logical concentrations. Thus, NDF/HRG is a dual specificity growth factor for 
human mammary epithelial cells, and the responsiveness of the cells to NDF/HRG 
is  influenced by the level of expression of erbB-2 receptors. 
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Normal human mammary epithelial cells proliferate 
in culture under defined serum-free conditions in re- 
sponse to growth factors that activate distinct signal 
transduction pathways (Stampfer et al., 1980; Ham- 
mond et al., 1984; Ethier et al., 1987, 1990). These cells 
require stimulation of the insulin-like growth factor 
(1GF)-I, receptor by either IGF-I, IGF-11, or supraphysi- 
ological concentrations of insulin (IN), and stimulation 
of the EGF receptor by either epidermal growth factor 
(EGF) or TGF-a. The presence of saturating concentra- 
tions of EGF does not induce cell growth in the absence 
of IGF-I and vice versa. Thus, these pathways interact 
synergistically to drive proliferation of human mam- 
mary epithelial cells. 
Recently, a family of growth factors that activates 
the erbB-2 receptors has been described (Holmes et al., 
1992; Wen et al., 1992). These factors, termed the neu 
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differentiation factors (NDF) or heregulins (HRG), bind 
directly to erbB-3 and erbB-4 receptors and can bind to 
heterodimers of erbB-2 and erbB-3, resulting in activa- 
tion of erbB-2 proteins (Plowman et al., 1993b; Kraus et 
al., 1993; Carraway et al., 1994; Sliwkowski et al., 
1994). Given that erbB-2, erbB-3, and erbB-4 are mem- 
bers of the EGF receptor family of proteins, one might 
predict that NDF/HRGs would have mitogenic activity 
similar to that of EGF. Therefore, we examined the 
ability of pure human recombinant NDF/HRG to sub- 
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stitute for EGF to induce proliferation of the human 
mammary epithelial cell line MCF-1OA. MCF-1OA 
cells, like primary cultures of normal human mam- 
mary epithelial cells, have a strict requirement for EGF 
and IGF-I for growth in serum-free culture (Ethier and 
Moorthy, 1991; Ethier et al., 1991). Not surprisingly, 
NDF/HRG was found to have mitogenic activity toward 
MCF-1OA cells when cultured in EGF-free medium. 
However, we also found that NDF/HRG can induce pro- 
liferation of MCF-1OA cells in EGF-containing medium 
that is devoid of insulin or IGF-I. Thus, our results 
indicate that NDF/HRG is a dual specificity growth 
factor that can substitute for both EGF and IGF-I to 
stimulate growth of human mammary epithelial cells. 
This property of NDFiHRG is, as far as we know, 
unique and is not shared by a number of other growth 
factors that we have studied, including transforming 
growth factor-a (TGF-a), IGF-I, IGF-11, acidic fibro- 
blast growth factor (FGF), bFGF, plate derived growth 
factor (PDGF), keratinocyte growth factor (KGF), or 
hepatocyte growth factor (HGF). This pleiotropic 
growth factor activity of NDF/HRG in mammary epi- 
thelial cells may explain the selective growth advan- 
tage that is acquired by human breast cancer cells as a 
result of amplification andor  overexpression of the 
c-erbB-2 gene. 
MATERIALS AND METHODS 
Cell culture conditions and assays for 
mitogenic activity 
MCF-1OA cells are a human mammary epithelial cell 
line that was isolated from nonmalignant breast tissue 
(Soule et al., 1990). In our laboratory, MCF-1OA cells 
are routinely cultured on type-I collagen-coated tissue 
culture dishes in serum-free Ham’s F-12 medium sup- 
plemented with bovine serum albumin, transferrin, 
ethanolamine, sodium selenite, triiodothyronine, insu- 
lin, hydrocortisone, and epidermal growth factor (Eth- 
ier and Moorthy, 1991; Ethier e t  al., 1991). To test for 
EGF-like or IGF-like activity of NDF/HRG, MCF-1OA 
cells were seeded in 35 mm collagen-coated wells a t  
3.5 x lo4 cells per well in Ham’s F-12 medium devoid of 
either insulin or EGF and containing 2% serum to al- 
low attachment. The next day, this plating medium was 
removed, and the cells were switched to the serum-free 
Ham’s F-12 medium described above but without either 
insulin or EGF and containing one of the NDF/HRG 
isoforms. The cells were grown for 7 days with two 
media changes, and the number of cells per dish was 
determined by counting isolated nuclei with a Coulter 
Counter as  described previously (Ethier e t  al., 1987). 
Human recombinant NDF/HRG used in these studies 
was kindly provided by Dr. Barry Ratzkin (Amgen Inc, 
Thousand Oaks, CAI. The various isoforms of NDF/ 
HRG were made in E. Coli and purified by reverse 
phase HPLC, and the purity was confirmed by N-termi- 
nal sequence analysis and gel electrophoresis. The se- 
quences of the various NDF/HRG isoforms has been 
published previously (Holmes et al., 1992). All of the 
isoforms were demonstrated to induce erbB-2 phospho- 
rylation in MDA-MB-453 cells. MCF-10-erbB-2 cells 
were kindly provided by Dr. David Salomon of the Na- 
tional Cancer Institute (Bethesda, MD). These cells 
were derived by infection of MCF-1OA cells with an  
amphotropic retroviral expession vector containing the 
full-length human erbB-2 cDNA (Ciardiello et al., 
1992). 
Immunoprecipitation and Western blot analysis 
For preparation of membranes to be used in Western 
blot experiments, confluent monolayers of cells were 
scraped in 20 mM HEPES containing 20 mM sodium 
orthovanadate, 10 mM sodium pyrophosphate, and 1 
mM phenylmethyl sulfonyl fluoride, dounced homoge- 
nized 50 times, and centrifuged at 800g for 10 min. The 
supernatant was then centrifuged a t  100,OOOg for 30 
min and the pellet resuspended in a lysis buffer consist- 
ing of 10 mM phosphate (pH 7.5), 100 mM NaC1, 1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 5 
mM sodium orthovanadate, and 10 mM sodium pyro- 
phosphate. The lysate was assayed for protein content, 
and then defined amounts of membrane protein were 
added to individual wells, electrophoresed, and blotted 
onto Imobilon-P membranes, blocked with 3% nonfat 
dry milk in Tris-buffered saline with 0.1% Tween-20; 
then blots were probed either with erbB-2 antibodies 
(Pab 9.3, kindly provided by Dr. Beatrice Langton, Ber- 
lex Biosciences, Richmond, CA) or anti-phosphoty- 
rosine antibodies (PY-20, ICN, Costa Mesa, CA). Pro- 
tein bands were visualized by incubating blots in 
biotinylated anti-rabbit (for Pab 9.3) or anti-mouse (for 
PY-20) IgG and then with Vectastain ABC reagents 
(Vector Laboratories, Burlingame, CA) using diami- 
nobenzidine as  a substrate. Alternatively, bands were 
visualized by Enhanced Chemoluminescence (Amer- 
sham, Arlington Heights, IL) following incubation in 
Vectastain ABC. 
For immunoprecipitation experiments, ten confluent 
60 mm dishes per group of MCF-1OA cells were lysed in 
a buffer consisting of 10 mM Tris (pH 7.6), 1% Triton 
X-100, 5 mM EDTA, 10 mM sodium pyrophosphate, 5 
mM sodium fluoride, 5 pM sodium orthovanadate, 
0.1% sodium azide, and 1 mM phenylmethyl sulfonyl 
fluoride. All ten plates were lysed in 200 pl lysis buffer 
by sequential addition of buffer from one plate to the 
next. Cells were scraped into the lysis buffer with a 
rubber policeman. The lysate was incubated on ice for 
15 min and then centrifuged a t  14,OOOg for 15 min. 
Next, 100 p1 of lysate was incubated with 100 pl of 
anti-phosphotyrosine-agarose (Oncogene Science, 
Union dale, NY) for 2 h at room temperature with agi- 
tation. The beads were washed three times by centrifu- 
gation at 2,OOOg for 1 min. Proteins were eluted from 
the beads by addition of lysis buffer containing 50 mM 
phenyl phosphate and incubating a t  room temperature 
for 2 h. The beads were then centrifuged, and the eluate 
was mixed with SDS-sample buffer, boiled for 5 min, 
and loaded onto a 7% SDS-polyacrylamide gel and elec- 
trophoresed. Following electrophoresis, the proteins 
were electroblotted and analyzed as  described above. 
RT-PCR for erbB-3 and erbB-4 
Oligonucleotide primers for RT-PCR were con- 
structed using published sequences of erbB-3 and 
erbB-4 mRNA (Kraus et al., 1989; Plowman et al., 
1990, 1993a). For reverse transcription of erbB-3 
mRNA, a 20-mer primer (5’-TCCGGGTGGCAGT- 
GAGAAGCA-3’) was synthesized complementary to 
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Fig. 1. Responsiveness of MCF-1OA cells to varying concentrations of 
EGF (A) when cultured in serum-free medium containing saturating 
concentrations of IGF-I (25 ng/ml) or to varying concentrations of 
IGF-I (B) when cultured in the presence of saturating concentrations 
of EGF (10 ng/ml). MCF-1OA cells were seeded at 3.5 X lo4 cells per 35 
mm well and cultured for 7 days in serum-free medium containing the 
positions 1744 to 1763 or erbB-3 mRNA. For PCR am- 
plification of erbB-3, a 22-mer upstream primer (5’- 
GACCGGCGATGCTGAGAACCAA-3’) was synthe- 
sized identical to positions 213 to 234 of erbB-3 mRNA 
and a 24-mer downstream primer (5‘-GGGCCCAAAG- 
CAGTGACCATTACA-3’) was synthesized complemen- 
tary to positions 739 to 762. The expected size of the 
erbB-3 PCR product is 550 base pairs. For reverse tran- 
scription of erbB-4 mRNA, a 20-mer primer (5‘-TCA- 
CACTGGGGGTCACACTC-3 ’) complementary to posi- 
tions 1693 to 1712 was utilized. PCR amplification of 
erbB-4 mRNA was performed using a 21-mer upstream 
primer identical to positions 252 to 272 of erbB-4 
mRNA and a 24-mer downstream primer (5’-AAGTC- 
TGGCAATGATT’M’CTGTGG-3’) complementary to 
positions 632 to 655. The expected size of the erbB-4 
PCR product is 404 base pairs. 
RNA from cells in one confluent 60 mm tissue cul- 
ture dish was isolated using the RNAzol B method (Tel- 
Test, Inc., Friendswood, TX). The final RNA pellet was 
washed with 75% ethanol, dried, and resuspended in 20 
pl DEPC-treated water. Ten microliters of this RNA 
preparation was used in the reverse transcription reac- 
tion in combination with 10 p15 x reverse transcription 
buffer (Boehringer Mannheim, Indianapolis, IN), 1 p1 
25mM dXTP solution, 2 pg reverse transcription 
primer, DEPC water to 50 pl, and 1 pl reverse tran- 
scriptase (Boehringer Mannheim). This mixture was 
incubated at 41°C for 1 h. The reverse transcriptase was 
then deactivated by heating the samples at 95°C for 2-3 
min. Ten microliters of the resulting cDNA was added 
to PCR tubes containing 5 p1 of 10 X adjust 
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indicated concentration of growth factor. The number of cells per dish 
was determined a t  the end of the experiment by counting isolated 
nuclei with a Coulter Counter. The results represent the mean num- 
ber of cells per well for triplicate wells and the error bars indicate the 
range. 
solution, 1 unit Taq polymerase (Boerhinger Man- 
nheim GmbH), and DEPC-treated water to 50 p1. Ther- 
mocycling was performed for 30 cycles at 94°C for 1 
min, 55°C for 1 min, and 72°C for 3 min. After thermo- 
cycling, each PCR sample was electrophoresed through 
a 3% Nusieve, 1% agarose minigel stained with ethid- 
ium bromide. 
RESULTS 
IGF-I and EGF requirements of MCF-1OA cells 
The human mammary epithelial cell line, MCF-lOA, 
expresses strict requirements for exogenous EGF and 
IGF-I (or supraphysiological concentrations of insulin) 
for growth in serum-free medium (Ethier and Moorthy, 
1991; Ethier et al., 1991). The data in Figure 1A,B show 
the responsiveness of these cells to varying concentra- 
tions of each factor when added to culture medium con- 
taining saturating concentrations (10 ngiml EGF, 25 
ng/ml IGF-I) of the complementing growth factor. Thus, 
EGF was present when IGF-I concentrations were var- 
ied and vice versa. These results indicate that prolifer- 
ation of MCF-1OA cells does not take place unless both 
factors are present. Furthermore, EGF-like factors 
such as TGF-a cannot substitute for IGF-I, and IGF- 
like factors such as insulin and IGF-I1 cannot substi- 
tute for EGF (unpublished observations). Thus, in 
MCF-1OA cells, like in primary cultures of human (Eth- 
ier et al., 1990) and rat mammary epithelial cells (Eth- 
ier et al., 1987), EGF and IGF-I interact synergistically 
to stimulate cell proliferation. 
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Fig. 2. Tyrosine phosphorylation of erbB-2 receptors in MCF-1OA 
cells exposed to various NDFiHRG isoforms. A MCF-1OA cells were 
incubated in EGF-free medium overnight and exposed to 10 ngiml of 
p2-NDFIHRG for 1 h. Cell lysates were immunoprecipitated using a 
phosphotyrosine antibody conjugated to agarose beads. The immuno- 
precipitate was electrophoresed and blotted, and the Western blot was 
probed with the erbB-%specific antibody Pab 9.3. B: Phosphotyrosine 
Western blot analysis of membrane protein obtained from MCF-1OA 
cells following exposure to one of the NDFiHRG isoforms. All cells 
NDF/HRG stimulation of erbB-2 in 
MCF-1OA cells 
To determine if exogenous NDF/HRG could activate 
erbB-2 receptors in MCF-1OA cells, monolayers of cells 
were grown to confluence in complete medium and 
switched to EGF-free medium overnight. The next day 
the cells were exposed to various NDF/HRG isoforms at 
a concentration of 10 ng/ml for 1 h. Phosphotyrosine 
Western blot analysis of membrane protein obtained 
from these cells shows clearly that NDF/HRG induces 
rapid tyrosine phosphorylation of a 185 kDa protein 
(Fig. 2B), and immunoprecipitation using phosphoty- 
rosine antibodies coupled to erb B-2 Western blot exper- 
iments showed that P-tyr-185 is the erbB-2 protein 
(Fig. 2A). The results of the Western blot experiments 
indicate that all of the alpha and beta isoforms of NDF/ 
HRG are capable of activating erbB-2 in these cells. 
Furthermore, the EGF domains of the p-isoforms were 
able to activate erbB-2 in these cells, whereas the EGF 
domain of the a2-isoform was not. Since it is now 
known that NDF/HRG does not activate erbB-2 di- 
rectly, RT-PCR analysis was carried out to determine if 
MCF-1OA cells express mRNA for either erbB-3 or 
erbB-4. RT-PCR analysis using erbB-3 primers yielded 
the predicted 550 base pair amplification product with 
both MCF-1OA cell RNA and SKBR-3 cell RNA which 
was used as a positive control (Kraus et al., 1989). RT- 
PCR analysis using erbB-4 primers yielded the pre- 
dicted 404 base pair amplification product in positive 
control T47D cells (Plowman et al., 1993a), but no prod- 
uct was observed using MCF-1OA cell RNA. In all 




were exposed to NDFiHRG for 1-h in EGF-free medium, and lane 1 
represents the control cells that were not exposed to NDFiHRG. C: 
RT-PCR analysis of erbB-3 and erbB-4 expression in MCF-1OA cells. 
Lane 1: MCF-1OA cells with erbR-3 primers. Lane 2: SkBr-3 cells 
with erbB-3 primers. Lanes 3,4 The same as 1 and 2 but without the 
reverse transcription step. Lane 5 MCF-1OA cells with erbB-4 prim- 
ers. Lane 6 T47D cells with erbB-4 primers. Lanes 7,s The same as 5 
and 6 but without the reverse transcription step. Lane 9 Size markers 
(+x 174RF DNA cut with HaeIII). 
verse transcription step was omitted yielded no ampli- 
fied products. Thus, these results indicate that MCF- 
10A cells express erbB-3 but not erbB-4 mRNA 
(Fig. 2C). The coexpression of erbB-2 and erbB-3 by 
MCF-1OA cells is consistent with their responsiveness 
to exogenous NDF/HRG (Peles et al., 1993; Carraway 
et al., 1994; Sliwkowski e t  al., 1994). 
EGF-like mitogenic activity of NDF/HRG 
To determine if exogenous NDFIHRG could substi- 
tute for EGF in stimulating growth of MCF-1OA cells, 
MCF-1OA cells were seeded at low density and grown 
for 7 days in serum-free, EGF-free medium that was 
supplemented with various NDF/HRG isoforms at a 
concentration of 10 ng/ml. The results of this experi- 
ment are shown in Figure 3A and indicate that MCF- 
1OA cells do not grow in EGF-free medium and that 
EGF can be replaced by NDFIHRG. In addition, the 
p-isoforms are significantly more potent mitogens than 
are the a-isoforms. As in the Western blot studies, the 
EGF domains of the p-isoforms were mitogenically ac- 
tive, whereas the EGF domain of the a 2  isoform was 
not. To compare the relative potencies of the different 
isoforms, similar experiments were performed using 
higher concentrations of the a-isoforms, and these re- 
sults are shown in Figure 3B. In tbe MCF-1OA cells, 
a2-NDF/HRG is mitogenic but is less than one-tenth as 
potent as the p2 isoform of NDF/HRG, as  50 ngiml of 
a2-NDF/HRG is less active than 5 ng/ml of the p2- 
isoform. Thus, these results show that activation of 
erbB-2 receptors by NDF/HRG results in proliferation 
of MCF-1OA cells in the absence of EGF and that there 
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Fig. 3. EGF-like mitogenic activity of NDF/HRG. IH indicates serum-free medium supplemented with 
insulin and hydrocortisone only. A MCF-1OA cells were cultured in serum-free, EGF-free medium in the 
presence of 10 ngiml of one of the NDF/HRG isoforms. The cells were cultured for 7 days as described in 
Figure 1. B: MCF-1OA cells were cultured in serum-free, EGF-free medium for 7 days in the presence of 
varying concentrations of either the a2- or p2-isoform of NDFIHRG. 
is an  isoform specificity for the mitogenic activity of 
this family of growth factors. 
IGF-like mitogenic activity of NDF/HRG 
Similar experiments were then performed to deter- 
mine if NDF/HRG could stimulate growth of MCF-1OA 
cells in medium supplemented with saturating concen- 
trations of EGF in the absence of insulin or IGF-I. The 
results shown in Figure 4A demonstrate that P2-NDFI 
HRG can stimulate proliferation of MCF-1OA cells in 
the absence of IGF-I and that maximal stimulation oc- 
curs a t  concentrations of approximately 10 ng/ml. The 
data in Figure 4B show that the isoform specificity 
noted earlier for the EGF-like effects of NDF/HRG is 
also operative for its IGF-like activity in that the a-iso- 
forms have little mitogenic activity in IGF-free me- 
dium at this concentration, This result highlights the 
unique dual specificity of NDF/HRG in which it acts 
both as an  IGF-like and EGF-like mitogen in stimulat- 
ing the growth of MCF-1OA cells. 
IGF-like activity of NDF/HRG in cells that 
overexpress erbB-2 receptors 
To determine if overexpression of the erbB-2 receptor 
would enhance the sensitivity of MCF-1OA cells to the 
mitogenic effects of NDF/HRG, experiments were car- 
ried out with MCF-1OA cells infected with a retroviral 
expression vector containing the full-length human 
c-erbB-2 gene (Ciardiello et al., 1992). These cells ex- 
press elevated levels of erbB-2 relative to parental 
MCF-1OA cells, and phosphotyrosine Western analysis 
indicated that erbB-2 is constitutively tyrosine phos- 
phorylated in these cells (Fig. 5). To examine the mito- 
genic activity of NDF/HRG in MCF-10-erbB-2 cells, 
growth assays were performed as described above using 
serum-free, IGF-1-free medium. The data shown in 
Figure 6A indicates that MCF-10-erbB-2 cells are more 
responsive to lower concentrations of P2-NDF/HRG, 
with maximum proliferation taking place at 1 .O ng/ml 
rather than 10 ng/ml required by the parental cells. 
The data shown in Figure 6B indicates that  MCF-10- 
erbB-2 cells are also responsive to the a2-isoform of 
NDFIHRG. Whereas parental MCF-1OA cells are es- 
sentially unresponsive to the a-isoforms of NDF/HRG 
under IGF-free conditions, MCF-10-erbB-2 cells are 
significantly growth stimulated by a2-NDF/HRG at 
physiological concentrations. Thus, these data indicate 
that overexpression of erbB-2 by mammary epithelial 
cells confers enhanced sensitivity to the IGF-I-like mi- 
togenic effects of all isoforms of NDF/HRG. 
In summary, the results of these studies indicate that 
NDF/HRG is a unique dual specificity growth factor 
that can stimulate mitogenic pathways normally acti- 
vated separately by EGF and IGF-I. Furthermore, cells 
that express elevated levels of erbB-2 exhibit an  en- 
hanced sensitivity to this family of growth factors. 
DISCUSSION 
The results of the experiments presented here indi- 
cate that NDF/HRG can induce tyrosine phosphoryla- 
tion of erbB-2 and stimulate proliferation of MCF-1OA 
human mammary epithelial cells. The results also indi- 
cate that there is a dramatic isoform specificity with 
regard to the mitogenic activity of NDFlHRG on these 
cells. Interestingly, this specificity is not reflected in 
the ability of the various isoforms to induce tyrosine 
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Fig, 4. IGF-like mitogenic activity of NDFIHRG. MCF-1OA cells were cultured in serum-free, IGF-free 
medium for 7 days in the presence of varying concentrations of the P2-isoform (A) or the u2-isoform of 
NDFIHRG. (B) Growth assays were performed as described above. HE indicates serum-free medium 
supplemented with hydrocortisone and EGF only. IHE indicates medium supplemented with insulin, 
hydrocortisone and EGF. 
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Fig. 5. Western blot analysis of erbB-2 expression and tyrosine phos- 
phorylation in MCF-1OA and MCF-lOerbB-2 cells. Western blots were 
prepared from membrane protein obtained from MCF-1OA or MCF-10- 
erbB-2 cells and probed either with an  erbB-%specific antibody Pab 
9.3 or with the anti-phosphotyrosine antibody PY-20. 
phosphorylation of erbB-2 receptors. Both the a- and 
p-isoforms of NDF/HRG have an  EGF-like domain with 
conserved positioning of cystene residues. Yet there are 
sequence differences within the EGF domain that dis- 
tinguish the two isoform types (Holmes et al., 1992). 
Since the EGF domain is known to be the receptor bind- 
ing domain, these differences may influence the affin- 
ity of the various isoforms for the receptor, and the 
proliferation assay may be more sensitive to those dif- 
ferences than is the phosphotyrosine Western blot as- 
say. The a-isoforms of NDF/HRG are mitogenic toward 
MCF-1OA cells, but ten- to twentyfold higher concen- 
trations of this factor are required to stimulate growth 
to a level equivalent to that obtained with the p-iso- 
forms. In addition, MCF-1OA-erbB-2 cells, which over- 
express erbB-2 receptors, exhibit increased responsive- 
ness to NDF/HRG and respond to the a-isoforms at 
physiological concentrations. These two observations 
are consistent with the hypothesis that affinity differ- 
ences between the a- and p-isoforms underlie the differ- 
ences in their mitogenic potential. 
The responsiveness of MCF-1OA cells to NDFiHRG is 
indicative of the presence of functioning erbB-3 recep- 
tors in these cells. RT-PCR experiments clearly demon- 
strated the presence of erbB-3 mRN in MCF-1OA cells. 
Given that NDFIHRG does not induce tyrosine phos- 
phorylation in cells that express erbB-2 in the absence 
of either erbB-3 or erbB-4 (Carraway et al., 1994; Peles 
et al., 1993; Plowman et al., 1993b) and that our RT- 
PCR experiments failed to detect erbB-4 mRNA in 
MCF-1OA cells, we conclude that erbB-2ierbB-3 inter- 
actions take place in MCF-1OA cells in response to 
NDF/HRG and drive the biological responses observed 
in these experiments. 
These studies also demonstrated that NDF/HRG is a 
dual specificity growth factor that can drive signal 
transduction pathways that normally require two dis- 
tinct classes of growth factors. Thus, NDFiHRG can 
substitute for either EGF or IGF-I to stimulate growth 
of MCF-1OA cells, and this is a unique property of this 
growth factor family. Results of recently published ex- 
periments may explain this interesting observation. As 
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Fig. 6. IGF-like mitogenic activity of NDF/HRG on MCF-10-erbB-2 cells. MCF-10-erbB-2 cells were 
cultured in serum-free, IGF-free medium for 7 days in the presence of varying concentrations of pP-NDFI 
HRG (A). B: The comparative response of MCF-10-erbB-2 cells and MCF-1OA cells to varying concentra- 
tions of the a2-isoform of NDFiHRG when cultured under IGF-free conditions. 
discussed above, erbB-2 receptors become activated in 
response to NDF/HRG when erbB-3 receptors are coex- 
pressed. Indeed, erbB-2lerbB-3 heterodimers bind 
NDFMRG with a higher affinity than do erbB-3 ho- 
modimers (Sliwkowski et al., 1994). This finding, cou- 
pled with results reported by Peles et al. (1991) and 
Fedi et al. (1994) suggest a mechanism for the dual 
activity of NDF/HRG observed in our experiments. Pe- 
les et al. (1991) demonstrated that activation of erbB-2 
receptors results in association and activation of signal- 
ing molecules such as phospholipase C-gamma in a 
manner similar to that observed with activated EGF 
receptors. More recently, Fedi et al. (1994) demon- 
strated that activation of erbB-3 receptors results in 
association of phosphatidyl inositol 3-kinase (PI 3-ki- 
nase) with erbB-3 receptors with ten- to twentyfold 
greater efficiency than occurs following activation of 
EGF receptors. The ability to bind to and activate PI-3 
kinase is a distinctive property of erbB-3 receptors that 
is not shared by either EGF receptors or erbB-2 recep- 
tors and is reflective of differences in the cytoplasmic 
domains between erbB-3 receptors and other members 
of the erbB family. Thus, erbB-3 receptors share signal 
transduction properties with molecules normally acti- 
vated as a result of IGF-I-induced signaling. Activa- 
tion of IGF-I receptors results in rapid phosphorylation 
of a substrate protein, IRS-1, which in turn binds to and 
activates (Backer et al., 1993). Thus, we propose that in 
cells that express erbB-2 receptors in conjunction with 
erbB-3 receptors and EGF receptors, stimulation by 
NDF/HRG results in activation of signal transduction 
pathways that are normally activated separately by 
EGF and IGF-I. This may occur by the formation of 
heterodimers among various erbB family members that 
yield both EGF-like signals and IGF-I-like signals. 
We have found that the potency of NDF/HRG to act 
as an IGF-like mitogen is influenced by the level of 
erbB-2 expression. This observation has significance 
for human breast cancer in that a substantial fraction 
of human breast cancers overexpress erbB-2 receptors 
that are constitutively activated (Slamon et al., 1987; 
Ro et al., 1989; Zeillinger et al., 1989). Furthermore, it 
has been reported that 90% of human breast cancer 
cells express erbB-3 receptors (Kraus et al., 1989). 
Thus, the overexpression and activation of erbB-2 re- 
ceptors in cells that coexpress erbB-3 receptors may 
result in breast cancer cells that are autonomous of 
both IGF-I-like and EGF-like mitogens for their prolif- 
eration. 
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